Amgen’s Repatha To Launch Next Week; Narrow Indication Mirrors Rival Praluent
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves PCSK9 inhibitor for use with statin therapy in adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease; drug priced at $14,100 annually for every two weeks administration.
You may also be interested in...
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.